252 related articles for article (PubMed ID: 28442502)
1. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
2. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
Das DS; Das A; Ray A; Song Y; Samur MK; Munshi NC; Chauhan D; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4280-4289. PubMed ID: 28270494
[No Abstract] [Full Text] [Related]
3. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
4. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
[No Abstract] [Full Text] [Related]
5. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
6. HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok JHL; Hedayat S; Zhang L; Aronson LI; Mirabella F; Pawlyn C; Bright MD; Wardell CP; Keats JJ; De Billy E; Rye CS; Chessum NEA; Jones K; Morgan GJ; Eccles SA; Workman P; Davies FE
Clin Cancer Res; 2018 May; 24(10):2395-2407. PubMed ID: 29391353
[No Abstract] [Full Text] [Related]
7. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
Volante M; Terzolo M; Fassnacht M; Rapa I; Germano A; Sbiera S; Daffara F; Sperone P; Scagliotti G; Allolio B; Papotti M; Berruti A
Clin Cancer Res; 2012 Jun; 18(12):3452-61. PubMed ID: 22547773
[TBL] [Abstract][Full Text] [Related]
9. [Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].
Tian N; Zhou L; Yang D; Wu H; Ma Y; Lü L; Wu S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):304-312. PubMed ID: 31068300
[TBL] [Abstract][Full Text] [Related]
10. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.
Hua Y; White-Gilbertson S; Kellner J; Rachidi S; Usmani SZ; Chiosis G; Depinho R; Li Z; Liu B
Clin Cancer Res; 2013 Nov; 19(22):6242-51. PubMed ID: 24077352
[TBL] [Abstract][Full Text] [Related]
11. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
12. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
[TBL] [Abstract][Full Text] [Related]
13. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Lou M; Liu Q; Ren G; Zeng J; Xiang X; Ding Y; Lin Q; Zhong T; Liu X; Zhu L; Qi H; Shen J; Li H; Shao J
J Biol Chem; 2017 Jun; 292(22):9136-9149. PubMed ID: 28411237
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
15. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
[TBL] [Abstract][Full Text] [Related]
16. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Fang Z; Song R; Gong C; Zhang X; Ren G; Li J; Chen Y; Qiu L; Mei L; Zhang R; Xiang X; Chen X; Shao J
Tumour Biol; 2016 Mar; 37(3):3515-26. PubMed ID: 26453115
[TBL] [Abstract][Full Text] [Related]
19. Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis.
Zhai B; Hou C; Xu R; Fang Y; Xiao H; Chen G; Wang X; Ma N; Han G; Wang R
Leuk Lymphoma; 2019 Oct; 60(10):2541-2548. PubMed ID: 30947584
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
